| Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | |||||||
Net loss | |||||||
-87,621 | -78,599 | -85,095 | -78,611 | -70,370 | 0 | 0 | 0 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Stock-based compensation | |||||||
4,961 | 4,550 | 4,613 | 4,104 | 3,431 | 0 | 0 | 0 |
Depreciation and amortization | |||||||
523 | 498 | 441 | 421 | 401 | 0 | 0 | 0 |
Amortization of right-of-use assets | |||||||
1,063 | 759 | 461 | 197 | 0 | 0 | 0 | 0 |
Accretion of discounts on marketable securities | |||||||
1,047 | 1,428 | 1,294 | 1,048 | 744 | 0 | 0 | 0 |
Realized gain on sale of available-for-sale securities | |||||||
6 | 6 | 4 | 2 | 0 | 0 | 0 | 0 |
Change in fair value of contingent repayment obligation | |||||||
-2,554 | -318 | -343 | -337 | -331 | 0 | 0 | 0 |
Changes in operating assets and liabilities: | |||||||
Prepaid expenses and other current assets | |||||||
1,595 | 3,961 | 8,264 | 7,830 | 2,385 | 0 | 0 | 0 |
Other assets | |||||||
651 | 1,187 | -2,359 | -103 | 673 | 0 | 0 | 0 |
Accounts payable | |||||||
4,009 | -738 | 5,239 | -857 | 916 | 0 | 0 | 0 |
Accrued liabilities | |||||||
-107 | 11,291 | 4,023 | 1,669 | 4,214 | 0 | 0 | 0 |
Deferred grant funding | |||||||
1,017 | -1,549 | -2,824 | -2,414 | -1,015 | 0 | 0 | 0 |
Lease related liabilities | |||||||
-1,213 | -903 | -597 | -173 | -123 | 0 | 0 | 0 |
Net cash used in operating activities | |||||||
-78,113 | -70,954 | -80,599 | -84,104 | -66,017 | 0 | 0 | 0 |
Cash flows from investing activities: | |||||||
Purchases of available-for-sale securities | |||||||
166,040 | 169,996 | 194,478 | 161,295 | 142,027 | 0 | 0 | 0 |
Proceeds from sales of available-for-sale securities | |||||||
3,996 | 3,996 | 3,996 | 3,996 | 0 | 0 | 0 | 0 |
Proceeds from maturities of available-for-sale securities | |||||||
176,177 | 163,190 | 155,603 | 117,599 | 78,241 | 0 | 0 | 0 |
Net cash provided by (used in) investing activities | |||||||
13,777 | -3,435 | -35,352 | -40,103 | -64,189 | 0 | 0 | 0 |
Cash flows from financing activities: | |||||||
Payments of deferred offering costs | |||||||
- | - | 0 | 0 | - | - | 0 | 0 |
Proceeds from issuance of common stock upon ESPP purchase | |||||||
859 | 859 | 588 | 588 | 0 | 0 | 0 | 0 |
Proceeds from issuance of common stock upon exercise of stock options | |||||||
2,130 | 1,551 | 1,538 | 1,080 | 291 | 0 | 0 | 0 |
Net cash provided by financing activities | |||||||
267,313 | 82,746 | 120,686 | 118,523 | 116,626 | 0 | 0 | 0 |
Net increase (decrease) in cash and cash equivalents | |||||||
202,977 | 8,357 | 4,735 | -5,684 | -13,580 | 0 | 0 | 0 |
Noncash investing and financing activities: | |||||||
Deferred offering costs included in accounts payable and accrued liabilities | |||||||
- | 0 | 0 | 0 | - | 0 | 0 | 0 |